News Update

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial

News Update
  ()
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer. read more >
News Update

Virtual HealthCare Tech Firm Contracts to Provide Patient Care Platform to US Nephrology Clinic

News Update
  ()
Reliq Health Technologies reported it signed a new agreement with a Texas-based nephrology clinic to provide its iUGO Care platform to patients with chronic kidney disease. read more >

Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck

  ()
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. read more >

Telehealth Tech Company Continues Rapid Growth in COVID-Changed Landscape

  ()
Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians. read more >

Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook

  ()
Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures. read more >

Analyst: All Systems Are Go for Testing, Testing and More Testing

Research Report
  ()
This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing. read more >
News Update

Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial

News Update
  ()
Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal. read more >

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer

  ()
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. read more >

Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition

Contributed Opinion
  ()
Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth. read more >
News Update

Virtual HealthCare Tech Firm Contracts with California Network of 500+ Doctors and 50 Clinics

News Update
  ()
Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California. read more >

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results

Research Report
  ()
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. read more >

PAVmed Shares Increase 28% after First US Patient Treated with CarpX Device for Carpal Tunnel Syndrome

  ()
PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX® Device, a minimally invasive carpal tunnel release surgical instrument. read more >

Expert Investing Ideas

"AGN [shares] are now in a vigorous uptrend."

–Clive Maund, CliveMaund.com


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook

  ()
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. read more >
News Update

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial

News Update
  ()
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. read more >

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial

  ()
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. read more >